FDA | What's New 中文 关注 FDA 批准塞尔帕替尼用于治疗局部晚期或转移性 RET 融合阳性实体瘤的传统适应症 FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors fda.gov
